All News
Filter News
Found 96 articles
-
MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update
5/9/2022
Mind Medicine today announced that it will host its earnings call on Monday, May 16, 2022 , at 8:30 a.m. EDT to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.
-
MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer
4/5/2022
Mind Medicine today announced the appointment of Francois Lilienthal, MD as Chief Commercial Officer.
-
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
3/24/2022
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), today announced it has received conditional approval from the Institutional Review Board (IRB) for its multi-site Phase 2b smoking cessation trial.
-
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
3/16/2022
Novamind Inc. is pleased to announce it has been selected by Mind Medicine, Inc. to host a phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder (GAD) in adults.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Shares of Mustang Bio have fallen more than 13% in premarket trading after announcing the FDA had placed a hold on the company’s Investigational New Drug application for its bubble boy gene therapy.
-
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
1/25/2022
Mind Medicine announced today that the U.S. Food and Drug Administration (FDA) has cleared MindMed's Investigational New Drug (IND) application, allowing the Company's Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD) to proceed.
-
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
1/4/2022
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), today announced the completion of its Phase 1 clinical trial of 18-MC, the Company's non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder.
-
MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event
12/30/2021
Mind Medicine today announced that MindMed's Chief Executive Officer and Director, Robert Barrow , will be participating in a panel and in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event on January 5-7, 2022.
-
MindMed Announces Transitions to Management Team
12/29/2021
Bradford Cross , Chief Technology Officer to transition; Don Gehlert , PhD, Chief Scientific Officer to transition to Senior Scientific Advisor.
-
MindMed to Participate at the Benzinga Global Small Cap Conference
12/2/2021
Mind Medicine today announced that MindMed's Chief Executive Officer, Robert Barrow, will provide a corporate update and the Company's management will participate in one-on-one investor meetings at the Benzinga Global Small Cap Conference to be held virtually on December 8-9, 2021.
-
MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
12/1/2021
Mind Medicine today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.
-
MindMed to Present at the Jefferies London Healthcare Conference
11/12/2021
Mind Medicine is pleased to announce that its CEO, Robert Barrow , will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19
-
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board
11/5/2021
Mind Medicine is pleased to announce the appointment of Maria A. Oquendo , M.D., Ph.D. to its Scientific Advisory Board.
-
MindMed to Present at Web Summit on Future of Mental Health
11/1/2021
Mind Medicine (MindMed) Inc. is pleased to announce that CEO Robert Barrow will be speaking at Web Summit, taking place on November 1-4, 2021 in Lisbon, Portugal .
-
MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration
9/23/2021
Mind Medicine and Liechti Lab is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany
-
MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference
9/10/2021
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021
-
MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference
9/9/2021
Mind Medicine is pleased to announce that its Chief Medical Officer, Daniel R. Karlin , MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference , which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.
-
MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes
9/2/2021
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), and BioXcel Therapeutics, Inc. ("BioXcel"), announce the publication of BioXcel's International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour.
-
CohBar Appoints Carol Nast to Its Board of Directors
8/16/2021
CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced the appointment of Carol Nast as an independent director on the company’s Board, effective August 11, 2021.